Tumor Biomarkers for Bacillus Calmette-Guérin Response: What We Get Is Not What We Want

Gottfrid Sjödahl; Carina Bernardo; Pontus Eriksson; Mattias Höglund; Fredrik Liedberg

doi:10.1016/j.euf.2023.03.001

Tumor Biomarkers for Bacillus Calmette-Guérin Response: What We Get Is Not What We Want

Eur Urol Focus. 2023 Jul;9(4):582-583. doi: 10.1016/j.euf.2023.03.001. Epub 2023 Mar 9.

Authors

Gottfrid Sjödahl¹, Carina Bernardo², Pontus Eriksson², Mattias Höglund², Fredrik Liedberg³

Affiliations

¹ Department of Translational Medicine, Division of Urological Research, Lund University, Lund, Sweden. Electronic address: gottfrid.sjodahl@med.lu.se.
² Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
³ Department of Translational Medicine, Division of Urological Research, Lund University, Lund, Sweden.

PMID: 36906485
DOI: 10.1016/j.euf.2023.03.001

Abstract

Studies to date on biomarkers predictive of response to bacillus Calmette-Guérin (BCG) treatment for non-muscle-invasive bladder cancer have only identified markers with prognostic potential. There is an urgent need for larger study cohorts and for control arms comprising BCG-untreated patients to identify biomarkers with true ability to predict BCG response in classifying this patient population.

MeSH terms

BCG Vaccine* / therapeutic use
Biomarkers, Tumor
Humans
Prognosis
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology

Substances

BCG Vaccine
Biomarkers, Tumor